EuroBiotech: More Articles of Note


> F-star named Darlene Deptula-Hicks as CFO. The appointment of a U.S.-based financial chief with experience at publicly traded biotechs comes as F-star increases its focus on internal assets. Release 

> BioNTech and Genmab began a first-in-human trial of a PD-L1x4-1BB bispecific in solid tumors. Statement  

> CyTuVax posted data from a phase 2 trial of hepatitis B vaccine HBAI20. The Dutch biotech thinks HBAI20 may work in non-responders to existing vaccines. Release  


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

> Oncopeptides presented phase 2 data on melflufen in multiple myeloma. Analysts at Jefferies said the response rate underscored the potential of the peptide-conjugated alkylator. Release  

> Oryzon posted dose-finding results from a phase 2 trial of Iadademstat in acute myeloid leukemia. Four-fifths of participants responded to the drug. Statement  

> Medigene shared an updated interim analysis of its acute myeloid leukemia trial. Two of the five early relapses showed mutational load upon entering the study. Release 

Suggested Articles

The FDA sent Eton's partner, Bausch Health, a complete response letter that raised “no concerns” about the clinical data in the drug’s application.

A new partnership will test drug cocktails containing Karyopharm's new product Xpovio in cell samples from glioblastoma patients.

Boehringer signed a deal to buy out a small immuno-oncology player this morning, and AbbVie’s been at it, too, inking a deal to snap up Mavupharma.